Literature DB >> 31655330

Short-term exposures to particulate matter gamma radiation activities and biomarkers of systemic inflammation and endothelial activation in COPD patients.

Shaodan Huang1, Eric Garshick2, Carolina L Z Vieira3, Stephanie T Grady4, Joel D Schwartz5, Brent A Coull6, Jaime E Hart7, Francine Laden5, Petros Koutrakis3.   

Abstract

BACKGROUND: We hypothesized that particulate matter (PM) gamma activity (gamma radiation associated with PM) is associated with systemic effects.
OBJECTIVE: Examine short-term relationships between ambient and indoor exposures to PM gamma activities with systemic inflammation and endothelial activation in chronic obstructive pulmonary disease (COPD) patients.
METHODS: In 85 COPD patients from Eastern Massachusetts, USA from 2012 to 2014, plasma C-reactive protein (CRP), interleukin-6 (IL-6), and soluble vascular cell adhesion molecule-1 (sVCAM-1) were measured seasonally up to four times. We used US EPA RadNet data measuring ambient gamma radiation attached to PM adjusted for background radiation, and estimated in-home gamma radiation exposures using the ratio of in-home-to-ambient sulfur in PM2.5. Linear mixed-effects regression models were used to determine associations between moving averages of PM gamma activities through the week before phlebotomy with these biomarkers. We explored ambient and indoor PM2.5, black carbon (BC), and NO2 as confounders.
RESULTS: Ambient and indoor PM gamma activities measured as energy spectra classes 3 through 9 were positively associated with CRP and IL-6. For example, averaged from phlebotomy day through previous 6 days, each IQR increase in indoor PM gamma activity for each spectra class, was associated with an CRP increase ranging from 7.45% (95%CI: 2.77, 12.4) to 13.4% (95%CI: 5.82, 21.4) and for ambient exposures were associated with an increase of 8.75% (95%CI: -0.57, 18.95) to 14.8% (95%CI: 4.5, 26.0). Indoor exposures were associated with IL-6 increase of 3.56% (95%CI: 0.31, 6.91) to 6.46% (95%CI:1.33, 11.85) and ambient exposures were associated with an increase of 0.03% (95%CI: -6.37, 6.87) to 3.50% (95%CI: -3.15, 10.61). There were no positive associations with sVCAM-1. Sensitivity analyses using two-pollutant models showed similar effects.
CONCLUSIONS: Our results demonstrate that short-term exposures to environmental PM gamma radiation activities were associated with systemic inflammation in COPD patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic obstructive pulmonary disease (COPD); Gamma radiation; Particulate matter (PM); Particulate matter gamma radiation activities; Systemic inflammatory biomarkers

Mesh:

Substances:

Year:  2019        PMID: 31655330      PMCID: PMC6983292          DOI: 10.1016/j.envres.2019.108841

Source DB:  PubMed          Journal:  Environ Res        ISSN: 0013-9351            Impact factor:   6.498


  30 in total

Review 1.  Air pollution and chronic airway diseases: what should people know and do?

Authors:  Xu-Qin Jiang; Xiao-Dong Mei; Di Feng
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

2.  Effect modification of ambient particle mortality by radon: A time series analysis in 108 U.S. cities.

Authors:  Annelise J Blomberg; Brent A Coull; Iny Jhun; Carolina L Z Vieira; Antonella Zanobetti; Eric Garshick; Joel Schwartz; Petros Koutrakis
Journal:  J Air Waste Manag Assoc       Date:  2019-01-15       Impact factor: 2.235

3.  Sites and structure of gamma radiation-induced DNA strand breaks.

Authors:  W D Henner; S M Grunberg; W A Haseltine
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

4.  Indoor black carbon and biomarkers of systemic inflammation and endothelial activation in COPD patients.

Authors:  Eric Garshick; Stephanie T Grady; Jaime E Hart; Brent A Coull; Joel D Schwartz; Francine Laden; Marilyn L Moy; Petros Koutrakis
Journal:  Environ Res       Date:  2018-05-18       Impact factor: 6.498

Review 5.  Systemic effects of chronic obstructive pulmonary disease.

Authors:  A G N Agustí; A Noguera; J Sauleda; E Sala; J Pons; X Busquets
Journal:  Eur Respir J       Date:  2003-02       Impact factor: 16.671

Review 6.  COPD Patients as Vulnerable Subpopulation for Exposure to Ambient Air Pollution.

Authors:  Joachim Heinrich; Tamara Schikowski
Journal:  Curr Environ Health Rep       Date:  2018-03

7.  Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.

Authors:  Alvar Agustí; Lisa D Edwards; Stephen I Rennard; William MacNee; Ruth Tal-Singer; Bruce E Miller; Jørgen Vestbo; David A Lomas; Peter M A Calverley; Emiel Wouters; Courtney Crim; Julie C Yates; Edwin K Silverman; Harvey O Coxson; Per Bakke; Ruth J Mayer; Bartolome Celli
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

8.  COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series).

Authors:  Francesca Polverino; Bartolome R Celli; Caroline A Owen
Journal:  Pulm Circ       Date:  2018 Jan-Mar       Impact factor: 3.017

9.  Urban-Rural County and State Differences in Chronic Obstructive Pulmonary Disease - United States, 2015.

Authors:  Janet B Croft; Anne G Wheaton; Yong Liu; Fang Xu; Hua Lu; Kevin A Matthews; Timothy J Cunningham; Yan Wang; James B Holt
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-02-23       Impact factor: 17.586

10.  Associations Between Ambient Particle Radioactivity and Blood Pressure: The NAS (Normative Aging Study).

Authors:  Marguerite M Nyhan; Brent A Coull; Annelise J Blomberg; Carol L Z Vieira; Eric Garshick; Abdulaziz Aba; Pantel Vokonas; Diane R Gold; Joel Schwartz; Petros Koutrakis
Journal:  J Am Heart Assoc       Date:  2018-03-15       Impact factor: 5.501

View more
  1 in total

1.  Cumulative effects of air pollution and climate drivers on COVID-19 multiwaves in Bucharest, Romania.

Authors:  Maria A Zoran; Roxana S Savastru; Dan M Savastru; Marina N Tautan
Journal:  Process Saf Environ Prot       Date:  2022-08-20       Impact factor: 7.926

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.